Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure–lowering activity in rodent eyes

PURPOSE: Glaucoma is a neurodegenerative disease of the eye with an estimated prevalence of more than 111.8 million patients worldwide by 2040, with at least 6 to 8 million projected to become bilaterally blind. Clinically, the current method of slowing glaucomatous vision loss is to reduce intraocu...

Descripción completa

Detalles Bibliográficos
Autores principales: Stankowska, Dorota L., Millar, J. Cameron, Kodati, Bindu, Behera, Sumita, Chaphalkar, Renuka M., Nguyen, Tam, Nguyen, Kytai T., Krishnamoorthy, Raghu R., Ellis, Dorette Z., Acharya, Suchismita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883929/
https://www.ncbi.nlm.nih.gov/pubmed/33633438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883929/
https://www.ncbi.nlm.nih.gov/pubmed/33633438

Ejemplares similares